Nivolumab

• Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting
  2024-518991-30-00 Phase IV 1 country Centre Francois Baclesse
• CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting
  2024-517789-41-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melano… Recruiting
  2024-519593-39-00 Phase III 1 country Karolinska University Hospital
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re… Recruiting
  2024-516650-22-00 Phase IV 1 country Institut Gustave Roussy
• Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur… Recruiting
  2024-516152-17-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting
  2023-503326-39-00 Phase III 1 country Institut Gustave Roussy
• CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission to… Recruiting
  2024-515885-15-00 Phase I/II 2 countries Universitair Medisch Centrum Groningen
• Phase II study of Roginolisib in UM patients Recruiting
  2024-514333-37-00 Phase II 2 countries iOnctura SA
• CHOPIN Recruiting
  2024-516127-14-01 Phase I (FiH) 1 country Leids Universitair Medisch Centrum (LUMC)
• Safe Stop Trial Melanoma Recruiting
  2024-516937-10-01 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting
  2023-508724-35-00 Phase II 1 country Unicancer
• Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting
  2024-518878-14-01 Phase IV 1 country Isala Klinieken Stichting
• A phase IB clinical trial on neoadjuvant and intraoperative intracranial administration of triple immune checkpoint blockade plus myeloid d… Recruiting
  2024-517842-33-01 Phase I (Other) 1 country UZ Brussel
• A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined … Recruiting
  2024-518891-29-00 Phase II 1 country Fondazione NIBIT Onlus
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 Phase III 3 countries North Estonia Medical Centre Foundation; Rigas Austrumu kliniska universitates s…
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting
  2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 Phase II/III 7 countries Ideaya Biosciences Inc.
• DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastat… Recruiting
  2023-504191-26-00 Phase II/III 1 country Universitaetsklinikum Regensburg
• EXLIBRIS : “EXL-01 combined with nivolumab for advanced NSCLC refractory to immunotherapy” Recruiting
  2023-505285-28-01 Phase I/II 1 country Centre Hospitalier Universitaire De Lille
• A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared … Recruiting
  2023-508156-20-00 Phase III 2 countries Vaestra Goetalandsregionen
• COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb… Recruiting
  2023-510089-28-00 Phase I/II 1 country Oslo University Hospital HF
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting
  2023-506753-38-00 Phase II 1 country Gercor
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 Phase III 10 countries Institut Gustave Roussy
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting
  2024-512999-35-00 Phase II 1 country Unicancer

Showing 49–72 of 205 trials